The arbovirus testing market size was valued at USD 1.25 billion in 2024 and is expected to reach USD 1.78 billion by 2032, growing at a CAGR of 4.59% over the forecast period of 2025-2032.
Strong government initiatives will drive the demand for the global arbovirus testing market. Surveillance, early detection, and outbreak control are being strengthened by public health authorities, driving demand for reliable diagnostics. It infuses money into research institutions and diagnostic companies so that tests are developed and available. Quality standards are assured by a regulatory system, thus enabling trustworthy diagnostics. Global partnerships, including WHO’s Global Arbovirus Initiative, support acceleration and out-of-the-box thinking. Information drives and upgrading laboratory facilities also increase testing capacity. These initiatives cumulatively increase the uptake of ELISA, RT-PCR, and point-of-care tests; thus, the support of the government is a significant market driver across the globe.
For instance, in October 2024, the CDC boosted arbovirus surveillance funding by USD 90 million, expanding RT-PCR testing in high-risk U.S. states including Florida, Texas, and California.Top of Form
The U.S. Arbovirus Testing Market was valued at USD 320.84 million in 2024 and is expected to reach USD 453.03 million by 2032, growing at a CAGR of 4.44% over 2025-2032.
The U.S. is dominating the arbovirus testing market as it has a strong integration of Telemedicine to facilitate remote consultation, early symptoms assessment, and ordering of tests, more so in the underserved areas. Virtual care facilitates outbreak surveillance decreases pressures on healthcare resources, and expands the reach of infectious diseases expertise. Improved patient tracking and digital adherence also support disease control. Furthermore, accommodative U.S. federal regulations and expanded reimbursements on telehealth have driven the adoption of remote diagnostic services, thereby enhancing access to RT-PCR and serological arbovirus testing solutions across the nation.
For instance, in April 2025, IN 2024, Telemedicine-based arbovirus consultations in the U.S. rose 48%, surpassing 1.2 million cases in 2024, driven by Medicare support and CDC-led programs.Top of FormTop of Form
Drivers:
Rising Global Incidence of Dengue and Zika, Driving the Arbovirus Testing Market Growth
The increasing prevalence of dengue and Zika globally is one of the leading factors that is driving the arbovirus testing market growth. Indeed, travel, climate change, and urbanization are expanding the ranges of the mosquito vectors, leading to increased exposure of populations to infection. With the surge in outbreaks, absence of antiviral drugs, and enormous socioeconomic burden, governments are focusing on early detection and infrastructure for diagnosis, which is expected to create a strong demand for arbovirus testing solutions globally.
For instance, in May 2025, WHO reported 6.8 million global dengue cases in early 2025, a 24% rise from 2024, significantly boosting global demand for arbovirus testing solutions.Top of Form
Restraints:
Supply Chain Disruptions, Restraining the Arbovirus Testing Market Growth
Lack of availability of the diagnosis system is a significant factor restraining the arbovirus testing market share. Poor infrastructure, cost, and reliance on central laboratories are constraints for testing in high-burden, low-resource regions. Limited awareness, diagnostic inaccuracies, and inadequate supply also restrict adoption. These impediments slow the detection of outbreaks and limit investment, which, in turn, limits the market opportunity in the regions where arbovirus testing is greatly needed.
For instance, in January 2025, PAHO reported over 40% underreporting of arboviral cases in rural Central America and the Caribbean due to poor lab access and limited trained personnel.
By Type
ELISA-based tests were the dominant segment in the arbovirus testing market analysis, with a market share of 46.86% in 2024, as they are inexpensive, scalable, and feasible in large screening programs, in particular in low- and middle-income countries. Their utility for surveillance, outbreak monitoring, and seroprevalence surveys is fuelling mass incorporation into public health systems, with substantial contributions to the total arbovirus testing market share globally.
RT-PCR-based tests are emerging as the fastest-growing segment in the arbovirus testing market trend, with a CAGR of 5.05%, owing to their high sensitivity, precision, and capability of early-infection screening. Their rapid uptake is driven by widespread outbreaks and the need for confirmatory diagnostics, and the growth of lab infrastructure in developing countries. These are substantial factors that are augmenting the global arbovirus testing market growth.
By End-user
In 2024, the Diagnostic Laboratories segment controlled the global arbovirus testing market share, driven by its excellent infrastructure, large-scale testing capacity, and importance for national surveillance and outbreak response. The ability to conduct FR-ELISA and RT-PCR testing with accurate outputs on a large scale has positioned them at the core of public health offering, which in turn, supports expanding the global market of arbovirus testing.
The Research Centers are the fastest-growing segment in the arbovirus testing industry, owing to the rise in R&D spending, new virus mutants, and the demand for new diagnostics, including CRISPR and isothermal tests. Their attention to creating fast, accurate, and field-ready tests enables early detection and global preparedness, and they are a major factor in fueling the global arbovirus testing market growth.
In 2024, the North American region dominated the arbovirus testing industry and accounted for 40.60% of the overall revenue share, owing to awareness of public and the early disease reporting systems in the region. In the U.S. and Canada, there is stronger education, travel advisories, and proactive public health alerts, so it is more likely that the patients and health care providers will pursue earlier testing. This leads to increased testing volume, more timely diagnosis, and rapid response in case of an outbreak, thus driving the overall demand for routine and emergency diagnostic test solutions. It also relies on technology preparedness, which will substantially increase North America's arbovirus testing market share due to the awareness-centric mode of its system.
The arbovirus testing market in Europe is growing steadily, owing to the spread of Aedes mosquitoes into southern and central Europe following climate change and warm temperatures. This has caused dengue outbreaks in Italy, France, and Spain. Compounding this are high levels of international travel, early uptake of diagnostics, and government-sponsored surveillance programmes driving testing volumes higher. The area is also spending on research and public health preparedness that will help to develop advanced-testing capabilities and deploy those technologies.
The Asia Pacific region is projected to grow with the fastest CAGR of 5.47% over the forecast period, owing to its high burden of endemic diseases, including dengue, Zika, and chikungunya, particularly in India, Indonesia, Thailand, and the Philippines. Due to recurrent epidemics, increased rate of urbanization, and disease-promoting effects of climate change, there has been an increased demand for early and accurate diagnosis. Governments around the region are pouring resources into public health infrastructure, mobile diagnostic labs, and point-of-care testing, to reach rural and remote areas. Moreover, increasing healthcare awareness, cross-national co-operation, and endorsements from the WHO and ASEAN will promote the adoption of testing. Large population pool and increasing healthcare spending in the region are also contributing to this growth, and thus, APAC is becoming an important market for the global arbovirus testing industry in the upcoming future.
The Middle East & Africa is the least attractive regions in the arbovirus testing market, owing to poor healthcare infrastructure, lack of diagnostic facilities, and low public health expenditure. Several areas do not have RT-PCR or ELISA capability and are dependent on minimum surveillance systems. Under-reporting, low patient awareness of the disease, and logistical difficulties in rural and remote areas hamper testing coverage, which prevents wide market penetration and overall growth in this high-burden but underserved region.
Latin America has a significant share in the global arbovirus testing industry, with a high prevalence of arboviral diseases including dengue, Zika, and chikungunya. Countries including Brazil, Mexico, and Colombia are hit by mass outbreaks and hence have a high need for diagnoses. Governments in the region have rolled out national surveillance programs, stepped up public health budgets, and disbursed millions of ELISA and RT-PCR test kits to fight the spiking infection rates. Urban crowding, the tropical climate, and the widespread infestation of Aedes aegypti mosquitoes are likely to ensure continued transmission and testing pressure.
Arbovirus testing companies include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Siemens Healthineers AG, QIAGEN N.V., Cepheid, bioMérieux SA, InBios International, Inc., Meridian Bioscience, Inc., and other players.
In April 2025, Thermo Fisher launched the TaqPath Tropical Virus Panel, a CE-marked RT-PCR assay for dengue, Zika, and chikungunya, enhancing molecular diagnostics and boosting the arbovirus testing market.
In March 2024, QIAGEN partnered with ICMR to develop a portable multiplex RT-PCR panel for dengue, chikungunya, and Japanese encephalitis, supporting outbreak control and expanding the arbovirus testing market.
| Report Attributes | Details |
| Market Size in 2024 | USD 1.25 billion |
| Market Size by 2032 | USD 1.78 billion |
| CAGR | CAGR of 4.59% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | "• By Type (ELISA-Based Tests, RT-PCR Based Tests, Other Test Types) •By End-user(Diagnostic Laboratories, Hospitals, Research Centers, Other End Use)" |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Siemens Healthineers AG, QIAGEN N.V., Cepheid, bioMérieux SA, InBios International, Inc., Meridian Bioscience, Inc.,and other players |
Ans. The current market size for the Arbovirus Testing Market is USD 1.30 billion.
Ans: Rising Global Incidence of Dengue and Zika, Driving the Arbovirus Testing Market Growth
Ans. North America regions are leading the growth in the Arbovirus Testing Market
Ans: The Arbovirus Testing Market is growing at a CAGR of 4.59% from 2025 to 2032.
Ans: Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Siemens Healthineers AG are the leading players in the global Arbovirus Testing Market.
Table of Content
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Rising Incidence & Prevalence of Arboviral Diseases (2023)
5.2 Rising Incidence & Prevalence of Arboviral Diseases (2023)
5.3 Device Volume & Usage Forecast (2020–2032)
5.4 Healthcare Spending on Arbovirus Diagnostics (2023)
5.5 Digital Health & Software Integration Trends (2023)
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion Plans and New Product Launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Peripheral Artery Disease Market Segmentation By Type
7.1 Chapter Overview
7.2 ELISA-Based Tests
7.2.1 ELISA-Based Tests Trend Analysis (2021-2032)
7.2.2 ELISA-Based Tests Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 RT-PCR Based Tests
7.3.1RT-PCR Based Tests Trends Analysis (2021-2032)
7.3.2 RT-PCR Based Tests Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Other Test Types
7.4.1Other Test Types Trends Analysis (2021-2032)
7.4.2 Other Test Types Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Peripheral Artery Disease Market Segmentation By End User
8.1 Chapter Overview
8.2 Diagnostic Laboratories
8.2.1 Diagnostic Laboratories Market Trends Analysis (2021-2032)
8.2.2 Diagnostic Laboratories Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Hospitals
8.3.1 Hospitals Market Trends Analysis (2021-2032)
8.3.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Research Centers
8.4.1 Research Centers Market Trends Analysis (2021-2032)
8.4.2 Research Centers Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Other End Use
8.5.1 Other End Use Market Trends Analysis (2021-2032)
8.5.2 Other End Use Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Peripheral Artery Disease Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.2.3 North America Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.4 North America Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.5.2 USA Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.6.2 Canada Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.7.2 Mexico Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.3 Europe
9.3.1 Trends Analysis
9.3.2 Europe Peripheral Artery Disease Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.3.3 Europe Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.4 Europe Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.3.5 Germany
9.3.5.1 Germany Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.5.2 Germany Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.3.6 France
9.3.6.1 France Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.6.2 France Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.3.7 UK
9.3.7.1 UK Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.7.2 UK Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.3.8 Italy
9.3.8.1 Italy Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.8.2 Italy Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.3.9 Spain
9.3.9.1 Spain Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.9.2 Spain Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.3.10 Poland
9.3.10.1 Poland Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.10.2 Poland Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.3.11 Turkey
9.3.11.1 Turkey Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.11.2 Turkey Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.3.12 Rest of Europe
9.3.12.1 Rest of Europe Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.12.2 Rest of Europe Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Peripheral Artery Disease Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.4.3 Asia Pacific Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.4 Asia Pacific Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.5.2 China Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.5.2 India Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.5.2 Japan Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.6.2 South Korea Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.4.7 Singapore
9.4.7.1 Singapore Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.7.2 Singapore Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
8.4.8 Australia
8.4.8.1 Australia Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
8.4.8.2 Australia Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.4.9 Rest of Asia Pacific
9.4.9.1 Rest of Asia Pacific Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.9.2 Rest of Asia Pacific Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.5 Middle East & Africa
9.5.1 Trends Analysis
9.5.2 Middle East & Africa Peripheral Artery Disease Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.5.3 Middle East & Africa Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.4 Middle East & Africa Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.5.5 UAE
9.5.5.1 UAE Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.5.2 UAE Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.5.6 Saudi Arabia
9.5.6.1 Saudi Arabia Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.6.2 Saudi Arabia Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.5.7 Qatar
9.5.7.1 Qatar Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.7.2 Qatar Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.5.8 South Africa
9.5.8.1 South Africa Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.8.2 South Africa Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.5.9 Middle East & Africa
9.5.9.1 Middle East & Africa Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.9.2 Middle East & Africa Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Peripheral Artery Disease Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.6.3 Latin America Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.4 Latin America Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.5.2 Brazil Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.6.2 Argentina Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
9.6.7 Rest of Latin America
9.6.7.1 Rest of Latin America Peripheral Artery Disease Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.7.2 Rest of Latin America Peripheral Artery Disease Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10. Company Profiles
10.1 Abbott Laboratories
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Product / Services Offered
10.1.4 SWOT Analysis
10.2 F. Hoffmann-La Roche Ltd.
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Product/ Services Offered
10.2.4 SWOT Analysis
10.3 Thermo Fisher Scientific Inc.
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Product/ Services Offered
10.3.4 SWOT Analysis
10.4 Bio-Rad Laboratories, Inc.
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Product/ Services Offered
10.4.4 SWOT Analysis
10.5 Siemens Healthineers AG
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Product/ Services Offered
10.5.4 SWOT Analysis
10.6 QIAGEN N.V.
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Product/ Services Offered
10.6.4 SWOT Analysis
10.7 Cepheid
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Product/ Services Offered
10.7.4 SWOT Analysis
10.8 bioMérieux SA
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Product/ Services Offered
10.8.4 SWOT Analysis
10.9 InBios International, Inc.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Product/ Services Offered
10.9.4 SWOT Analysis
10.10 Meridian Bioscience, Inc.
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Product/ Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Type
ELISA-Based Tests
RT-PCR Based Tests
Other Test Types
By End-user
Diagnostic Laboratories
Hospitals
Research Centers
Other End Use
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players